3E Bioventures
3E Bioventures is a venture capital firm specializing in growth capital.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed 3E Bioventures Information
Geographic Data
Address: One First Street Suite 18
City: Los Altos
State: CA
Zip: 94022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
3,879,630Website Global Rank
3,030Website Monthly Traffic
Twitter Followers
Description
3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground China experiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2018 | Cytek Biosciences | Series C | - |
| 1/2016 | Refuge Biotechnologies | Series A | 8.9M |
| 9/2022 | Si Peng Technology | Angel Round | - |
| 1/2017 | OncoImmune | Series A | 15M |
| 12/2015 | Profusa | Series B | 13.2M |
| 11/2021 | Novlead Biotech | Series B | 18.8M |
| 10/2019 | Ansun BioPharma | Series B | 100M |
| 8/2018 | Apexigen | Series C | 58M |
| 11/2017 | Ligatech Bioscience | Series A | - |
| 3/2020 | Apexigen | Series C | 65M |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 9/2020 | OncoImmune | Series B | 56M |
| 5/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 3/2020 | Lipidio Pharmaceuticals | Series A | - |
| 12/2021 | ITabMed | Series A | 20M |
| 11/2022 | Subtle Medical | Series B | 25M |
| 4/2017 | EpimAb Biotherapeutics | Series A | 25M |
| 5/2018 | Refuge Biotechnologies | Series B | 0 |
| 1/2021 | Cardea Bio | Series A | 0 |
| 8/2018 | Profusa | Series C | 0 |
| 9/2020 | Biocytogen | Series D | 143M |
| 8/2021 | NeuralGalaxy | Series A | 0 |
| 4/2018 | Biocytogen | Series C | 65.3M |
| 12/2018 | Medtrum | Series C | 29.1M |
| 5/2018 | Ansun BioPharma | Series A | 85M |
| 8/2022 | Regenacy Pharmaceuticals | Series B | 0 |
| 3/2020 | Regenacy Pharmaceuticals | Series A | - |
| 9/2016 | MicuRx Pharmaceuticals | Series C | 55M |
| 4/2023 | Xunyuan Technology | Angel Round | - |
| 1/2023 | Junhemeng Biopharmaceutical | Series A | 0 |
| 1/2022 | Dermaliq Therapeutics | Series A | 0 |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 9/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 6/2023 | Novlead Biotech | Series B | - |
| 11/2020 | Subtle Medical | Series A | 12.2M |
| 3/2022 | CytoNiche | Series B | 0 |
| 2/2023 | Eluminex Biosciences | Series B | 40M |
| 8/2019 | Biocytogen | Series D | 77.1M |
| 12/2021 | Boaoxin | Venture Round | 0 |
| 8/2019 | Doctor Shaoyang | Series A | 7.1M |
| 3/2018 | Eucure Biopharma | Series B | 19.1M |
| 12/2021 | Zhengli Technology | Venture Round | - |
| 2/2021 | Cullgen | Series B | 0 |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 4/2023 | Xunyuan Technology | Angel Round | - |
| 2/2023 | Eluminex Biosciences | Series B | 0 |
| 1/2023 | Junhemeng Biopharmaceutical | Series A | 0 |
| 9/2022 | Si Peng Technology | Angel Round | - |
| 8/2022 | Regenacy Pharmaceuticals | Series B | 0 |
| 3/2022 | CytoNiche | Series B | 0 |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 1/2022 | Dermaliq Therapeutics | Series A | 0 |
| 12/2021 | Zhengli Technology | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
